Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 5 Hz electroacupuncture combined tipronone capsules, Simple tipronone capsules group(The basic treatment group).
- Who it may be relevant to
- Registry conditions: Chronic Atrophic Gastritis. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of the Efficacy of Electroacupuncture in the Treatment of Chronic Atrophic Gastritis: A Randomized Controlled Trial
Overview
Brief Summary Template for the Study: This clinical trial aims to evaluate whether electroacupuncture can treat chronic atrophic gastritis (CAG) in adult subjects aged 18 to 75 years (including both males and females), all of whom have been diagnosed with CAG based on endoscopic and histopathological criteria. The primary objectives of this study are to answer the following questions: * Can 5 Hz electroacupuncture therapy reverse the pathological state of the gastric mucosa in patients with chronic atrophic gastritis? * Can 5 Hz electroacupuncture therapy improve gastrointestinal symptoms in patients with chronic atrophic gastritis? * Is there a difference in efficacy between the combination of 5 Hz electroacupuncture therapy and gastric mucosa protectants versus the use of gastric mucosa protectants alone in the treatment of chronic atrophic gastritis? Researchers will compare the effects of 5 Hz electroacupuncture combined with gastric mucosal protectants versus gastric mucosal protectants alone to determine which method can reverse the pathological state of gastric mucosa and provide more significant symptom relief. Participants will: * Receive acupuncture treatment at specific acupoints (such as Shangwan(CV13), Zhongwan (CV12) ,Xiawan(CV10), Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39).) Electroacupuncture is administered at the abdominal points 'CV13-CV12' and 'ST21-ST21', alongside bilateral lower limb points 'ST36-ST39', using an SDZ-IIB handheld electroacupuncture device (Huatuo brand, Suzhou Medical Supplies Factory Co., Ltd.). Receive electroacupuncture treatment at 5Hz.for 30-minute sessions, three times weekly for 1-8 weeks; twice weekly from weeks 9 to 16, once weekly from weeks 17 to 24, for a total of 24 weeks, comprising 48 treatment sessions. * Be randomly assigned to one of the following groups: 5 Hz electroacupuncture combined with gastric mucosal protective agent group or gastric mucosal protective agent group (control group). * Have their dyspepsia symptoms, quality of life, and any adverse reactions continuously monitored and assessed throughout the study period.
Interventions
- Other 5 Hz electroacupuncture combined tipronone capsules
Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. Shangwan(CV13), Zhongwan (CV12) ,Xiawan(CV10), Liangmen (ST21), Tianshu (ST25), Zusanli (ST36), and Xiajuxu (ST39). Disposable needles will be inserted until the "deqi" sensation is achieved. Electro - Drug Simple tipronone capsules group(The basic treatment group)
Patients in the Simple tipronone capsules group(basic treatment group) will receive only conventional basic drug therapy. They will be given Svi-Shu (tipronone capsules) (Eisai Pharmaceutical Co., Ltd., national drug approval number H20093656, specification: 50 mg) orally, one capsule at a time, three times a day, after meals.
Primary outcome measures
- Total pathological response rate after 24 weeks of intervention [Time frame: 24 weeks after the start of treatment.]
Secondary outcome measures (9)
- Histological scoring of pathological variables [Time frame: 24 weeks after the start of treatment.]
- Serum pepsinogen I and II (pepsinogen I, pepsinogen II, PG I, PG II), serum pepsinogen ratio (PGR), and gastrin-17 (Gastrin-17) levels. [Time frame: 24 weeks after the start of treatment.]
- Global Overall Symptom (GOS) Score Change [Time frame: Baseline, Week 12, Week 24]
- Hospital Anxiety and Depression Scale (HADS) Score Change [Time frame: Baseline, Week 12, Week 24]
- Visual analogue scale (VAS) score for upper abdominal pain [Time frame: Baseline, Week 12, Week 24]
- Upper abdominal pain diary [Time frame: Baseline to Week 24]
- Pittsburgh Sleep Quality Index (PSQI) [Time frame: Baseline, Week 12, Week 24]
- Treatment Expectation Score [Time frame: Prior to the first treatment (Baseline)]
- Compliance evaluation [Time frame: Baseline, Week 12, Week 24]
Eligibility criteria
Inclusion criteria
- Meets the diagnostic criteria for chronic atrophic gastritis (CAG) (at the time of enrolment, participants must provide reports from endoscopic and pathological examinations conducted within the past year prior to the study start date, both of which indicate chronic atrophic gastritis)
- Age between 18 and 75 years old, no gender restrictions;
- Has not received acupuncture treatment within the past month;
- Not participated in any other ongoing studies within the past 2 months.
- Understand and agree to participate in this study and sign the informed consent form.
Exclusion criteria
- Autoimmune gastritis (type A chronic atrophic gastritis);
- Participants with a positive C-13 urea breath test at baseline (Helicobacter pylori infection);
- Patients diagnosed with high-grade intraepithelial neoplasia based on upper gastrointestinal endoscopy and gastric mucosal biopsy pathology;
- Patients with confirmed or unresolved malignant tumours, particularly oesophageal cancer and gastric cancer; patients with other upper gastrointestinal lesions such as peptic ulcers or Barrett's oesophagus;
- Patients with severe lesions in major organs (heart, liver, kidney, lung, etc.) or other autoimmune diseases (rheumatic diseases, Crohn's disease, autoimmune pancreatitis, etc.); Persons with cardiac pacemakers;
- Pregnant and lactating women;
- Patients with infectious diseases such as tuberculosis, hepatitis, or HIV/AIDS;
- Individuals with a history of alcohol abuse, drug use, or illicit drug use;
- Individuals who have used other prokinetic agents, mucosal protectants, acid-suppressing medications, or related traditional Chinese medicines within the past two weeks;
- Individuals currently participating in or who have participated in other clinical trials within the past two months; individuals unable to tolerate acupuncture or with contraindications for acupuncture treatment; and individuals deemed unsuitable for participation in this clinical trial by the research team.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 3 centers
- Hangzhou TCM Hospital of Zhejiang Chinese Medical University (Hangzhou Hospital of Traditi — Hangzhou
- Hangzhou First People's Hospital — Hangzhou
- The Third Affiliated Hospital of Zhejiang Chinese Medicinal University — Hangzhou
Identifiers
NCT: NCT07152860 · 20250804103318839